Effective suppression of Dengue virus using a novel group-I intron that induces apoptotic cell death upon infection through conditional expression of the Bax C-terminal domain

Introduction: Approximately 100 million confirmed infections and 20,000 deaths are caused by Dengue virus (DENV) outbreaks annually. Global warming and rapid dispersal have resulted in DENV epidemics in formally non-endemic regions. Currently no consistently effective preventive measures for DENV exist, prompting development of transgenic and paratransgenic vector control approaches. Production of transgenic mosquitoes refractory for virus infection and/or transmission is contingent upon defining antiviral genes that have low probability for allowing escape mutations, and are equally effective against multiple serotypes. Previously we demonstrated the effectiveness of an anti-viral group I intron targeting U143 of the DENV genome in mediating trans-splicing and expression of a marker gene with the capsid coding domain. In this report we examine the effectiveness of coupling expression of ΔN Bax to trans-splicing U143 intron activity as a means of suppressing DENV infection of mosquito cells. Results: Targeting the conserved DENV circularization sequence (CS) by U143 intron trans-splicing activity appends a 3’ exon RNA encoding ΔN Bax to the capsid coding region of the genomic RNA, resulting in a chimeric protein that induces premature cell death upon infection. TCID50-IFA analyses demonstrate an enhancement of DENV suppression for all DENV serotypes tested over the identical group I intron coupled with the non-apoptotic inducing firefly luciferase as the 3’ exon. These cumulative results confirm the increased effectiveness of this αDENV-U143-ΔN Bax group I intron as a sequence specific antiviral that should be useful for suppression of DENV in transgenic mosquitoes. Annexin V staining, caspase 3 assays, and DNA ladder observations confirm DCA-ΔN Bax fusion protein expression induces apoptotic cell death. Conclusion: This report confirms the relative effectiveness of an anti-DENV group I intron coupled to an apoptosis-inducing ΔN Bax 3’ exon that trans-splices conserved sequences of the 5’ CS region of all DENV serotypes and induces apoptotic cell death upon infection. Our results confirm coupling the targeted ribozyme capabilities of the group I intron with the generation of an apoptosis-inducing transcript increases the effectiveness of infection suppression, improving the prospects of this unique approach as a means of inducing transgenic refractoriness in mosquitoes for all serotypes of this important disease

Targeting of highly conserved Dengue virus sequences with anti-Dengue virus trans-splicing group I introns

<p>Abstract</p> <p>Background</p> <p>Dengue viruses (DENV) are one of the most important viral diseases in the world with approximately 100 million infections and 200,000 deaths each year. The current lack of an approved tetravalent vaccine and ineffective insecticide control measures warrant a search for alternatives to effectively combat DENV. The <it>trans</it>-splicing variant of the <it>Tetrahymena thermophila </it>group I intron catalytic RNA, or ribozyme, is a powerful tool for post-transcriptional RNA modification. The nature of the ribozyme and the predictability with which it can be directed makes it a powerful tool for modifying RNA in nearly any cell type without the need for genome-altering gene therapy techniques or dependence on native cofactors.</p> <p>Results</p> <p>Several anti-DENV Group I <it>trans</it>-splicing introns (αDENV-GrpIs) were designed and tested for their ability to target DENV-2 NGC genomes <it>in situ</it>. We have successfully targeted two different uracil bases on the positive sense genomic strand within the highly conserved 5'-3' cyclization sequence (CS) region common to all serotypes of DENV with our αDENV-GrpIs. Our ribozymes have demonstrated ability to specifically <it>trans</it>-splice a new RNA sequence downstream of the targeted site <it>in vitro </it>and in transfected insect cells as analyzed by firefly luciferase and RT-PCR assays. The effectiveness of these αDENV-GrpIs to target infecting DENV genomes is also validated in transfected or transformed Aedes mosquito cell lines upon infection with unattenuated DENV-2 NGC.</p> <p>Conclusions</p> <p>Analysis shows that our αDENV-GrpIs have the ability to effectively <it>trans</it>-splice the DENV genome <it>in situ</it>. Notably, these results show that the αDENV-GrpI 9v1, designed to be active against all forms of Dengue virus, effectively targeted the DENV-2 NGC genome in a sequence specific manner. These novel αDENV-GrpI introns provide a striking alternative to other RNA based approaches for the transgenic suppression of DENV in transformed mosquito cells and tissues.</p

Effective suppression of Dengue fever virus in mosquito cell cultures using retroviral transduction of hammerhead ribozymes targeting the viral genome

Outbreaks of Dengue impose a heavy economic burden on developing countries in terms of vector control and human morbidity. Effective vaccines against all four serotypes of Dengue are in development, but population replacement with transgenic vectors unable to transmit the virus might ultimately prove to be an effective approach to disease suppression, or even eradication. A key element of the refractory transgenic vector approach is the development of transgenes that effectively prohibit viral transmission. In this report we test the effectiveness of several hammerhead ribozymes for suppressing DENV in lentivirus-transduced mosquito cells in an attempt to mimic the transgenic use of these effector molecules in mosquitoes. A lentivirus vector that expresses these ribozymes as a fusion RNA molecule using an Ae. aegypti tRNAval promoter and terminating with a 60A tail insures optimal expression, localization, and activity of the hammerhead ribozyme against the DENV genome. Among the 14 hammerhead ribozymes we designed to attack the DENV-2 NGC genome, several appear to be relatively effective in reducing virus production from transduced cells by as much as 2 logs. Among the sequences targeted are 10 that are conserved among all DENV serotype 2 strains. Our results confirm that hammerhead ribozymes can be effective in suppressing DENV in a transgenic approach, and provide an alternative or supplementary approach to proposed siRNA strategies for DENV suppression in transgenic mosquitoes

The Canadian Healthy Infant Longitudinal Development (CHILD) birth cohort study: Assessment of environmental exposures

The Canadian Healthy Infant Longitudinal Development birth cohort was designed to elucidate interactions between environment and genetics underlying development of asthma and allergy. Over 3600 pregnant mothers were recruited from the general population in four provinces with diverse environments. The child is followed to age 5 years, with prospective characterization of diverse exposures during this critical period. Key exposure domains include indoor and outdoor air pollutants, inhalation, ingestion and dermal uptake of chemicals, mold, dampness, biological allergens, pets and pests, housing structure, and living behavior, together with infections, nutrition, psychosocial environment, and medications. Assessments of early life exposures are focused on those linked to inflammatory responses driven by the acquired and innate immune systems. Mothers complete extensive environmental questionnaires including time-activity behavior at recruitment and when the child is 3, 6, 12, 24, 30, 36, 48, and 60 months old. House dust collected during a thorough home assessment at 3–4 months, and biological specimens obtained for multiple exposure-related measurements, are archived for analyses. Geo-locations of homes and daycares and land-use regression for estimating traffic-related air pollution complement time-activity-behavior data to provide comprehensive individual exposure profiles. Several analytical frameworks are proposed to address the many interacting exposure variables and potential issues of co-linearity in this complex data set

Spin state behavior of iron(II)/dipyrazolylpyridine complexes. New insights from crystallographic and solution measurements

The isomeric complexes [Fe(1-bpp)2]2+ and [Fe(3-bpp)2]2+ (1-bpp=2,6-di[pyrazol-1-yl]pyridine; 3-bpp=2,6-di[1H-pyrazol-3-yl]pyridine) and their derivatives are some of the most widely investigated complexes in spin-crossover research. This article addresses two unique aspects of their spin-state chemistry. First, is an unusual structural distortion in the high-spin form that can inhibit spin-crossover in the solid state. A new analysis of these structures using continuous shape measures has explained this distortion in terms of its effect on the metal coordination geometry, and has shown that the most highly distorted structures are a consequence of crystal packing effects. Second, solution studies have quantified the influence of second-sphere hydrogen bonding on spin-crossover in [Fe(3-bpp)2]2+, which responds to the presence of different anions and solvents (especially water). Previously unpublished data from the unsymmetric isomer [Fe(1,3-bpp)2]2+ (1,3-bpp=2-[pyrazol-1-yl]-6-[1H-pyrazol-3-yl]pyridine) are presented for comparison. Modifications to the structure of [Fe(3-bpp)2]2+, intended to augment these supramolecular effects, are also described

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Suppression of the Arboviruses Dengue and Chikungunya Using a Dual-Acting Group-I Intron Coupled with Conditional Expression of the Bax C-Terminal Domain

<div><p>In portions of South Asia, vectors and patients co-infected with dengue (DENV) and chikungunya (CHIKV) are on the rise, with the potential for this occurrence in other regions of the world, for example the United States. Therefore, we engineered an antiviral approach that suppresses the replication of both arboviruses in mosquito cells using a single antiviral group I intron. We devised unique configurations of internal, external, and guide sequences that permit homologous recognition and splicing with conserved target sequences in the genomes of both viruses using a single trans-splicing Group I intron, and examined their effectiveness to suppress infections of DENV and CHIKV in mosquito cells when coupled with a proapoptotic 3' exon, ΔN Bax. RT-PCR demonstrated the utility of these introns in trans-splicing the ΔN Bax sequence downstream of either the DENV or CHIKV target site in transformed <i>Aedes albopictus</i> C6/36 cells, independent of the order in which the virus specific targeting sequences were inserted into the construct. This trans-splicing reaction forms DENV or CHIKV ΔN Bax RNA fusions that led to apoptotic cell death as evidenced by annexin V staining, caspase, and DNA fragmentation assays. TCID50-IFA analyses demonstrate effective suppression of DENV and CHIKV infections by our anti-arbovirus group I intron approach. This represents the first report of a dual-acting Group I intron, and demonstrates that we can target DENV and CHIKV RNAs in a sequence specific manner with a single, uniquely configured CHIKV/DENV dual targeting group I intron, leading to replication suppression of both arboviruses, and thus providing a promising single antiviral for the transgenic suppression of multiple arboviruses.</p></div

Schematic Representation of the A. CHIKV and B. DENV genomes, respectively, with regions targeted by the Dual Targeting Introns.

<p><b>A</b>. CHIKV genomic RNA diagram with the indicated conserved region targeted for viral suppression. The CHIKV conserved domain, labeled as the CHIKV Conserved Region, was determined through a Clustal X alignment of GenBank obtained CHIKV sequences (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139899#sec011" target="_blank">Materials and Methods</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139899#pone.0139899.s005" target="_blank">S5 Fig</a>). <b>B</b>. The most invariant segments of the DENV RNA are known as the 5’ and 3’ cyclization sequences (labeled as the Group I Intron target site). These sequences are so named because they are complementary to each other and are thought to be involved in the formation of a panhandle structure during genome replication.</p

anti-CHIKV/DENV Dual Targeting Introns in a Bicistronic Configuration.

<p>Each of the <i>trans</i>-splicing dual targeting introns was tagged downstream of the ΔN Bax 3’ exon (active, further truncated version of tBax) with the mCherry fluorescent marker gene expressed from an IRES sequence of the Drosophila C Virus (DCV). Expression of these constructs was driven by the <i>Drosophila melanogaster</i> Actin 5c promoter. Each of these Dicistrovirus IRES sequences was previously determined to yield the highest levels of expression in <i>Ae</i>. <i>aegypti</i> mosquito cells [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139899#pone.0139899.ref048" target="_blank">48</a>]. The bicistronic configuration allowed monitoring for the presence and expression of these constructs within cell cultures through dual expression of antiviral intron-ΔN Bax and mCherry cistronic portions of the plasmid. Version 1 (v1) and Version 2 (v2) refer to the order of the CHIKV and DENV specific P10 helix sequences. CHIKV = Chikungunya virus targeting sequences; DENV = Dengue virus targeting sequences; IRES = internal ribosome entry site; EGS = external guide sequence; IGS = internal guide sequence; BL = bulge loop; TSD = <i>trans</i> splicing domain; P10 = P10 helix.</p

Effector caspase activation confirms the induction of apoptosis by the activation of Dual Targeting Intron Constructs.

<p>Clonal <i>Ae</i>. <i>albopictus</i> C6/36 cells transformed with the single or anti-CHIKV/DENV dual targeting antiviral intron constructs indicated were challenged with either of the four DENV serotypes or CHIKV vaccine strain 181/25 (MOI 0.01). 1x10⁶ cells were assessed for effector caspase activity, per the manufacturer’s instructions (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139899#sec011" target="_blank">Materials and Methods</a>). ΔC/D-ΔN Bax or Δ/C-ΔN Bax refer to the anti- CHIKV/DENV dual targeting introns possessing the inactive deletion mutation of the <i>trans</i>-splicing domain that is linked to the ΔN Bax 3’ exon. Wt (wild type) refers to a negative control C6/36 cell line that does not express antiviral intron constructs. Numbered lanes indicate clonal cell populations expressing single or dual virus targeting intron constructs. Three wells were infected per clonal cell population and analyzed for “effector caspase” activity. The experiment was performed at three independent times resulting in a total of nine replicates for each dual-targeting intron-ΔN Bax tested.</p